Contract
Exhibit 4.7
8 November 2016
Xxxxxxx Xxxxx
Chief Executive Officer
Advance Accelerator Applications
00 xxx Xxxxxx, 00000
Saint-Genis-Pouilly
France
Dear Xx. Xxxxx:
In response to a request from your Head of Legal Xxxxxx Xxxxxx, this letter is intended to clarify the status of the Clinical Services Agreement (the “Agreement”) between Advanced Accelerator Applications (hereafter to be referred to as “Sponsor”) and Accelovance Europe S.r.l. (hereinafter to be referred to as “Accelovance”) with respect to the clinical trial known as, “A multicenter, stratified, open, randomized, comparator-controlled, paral lel groups phase III study comparing treatment with 177Lu-DOTAO-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumours” (the “Study”). The initial Agreement was entered into by Pierrel Research Italy Spa on 1 November 2011.
With this letter, Accelovance certifies that it is the registered legal entity that has entered into the Agreement with the Sponsor (Italian fiscal code registration number 03777940374) and it will continue to be bound by and honor the terms of the Agreement as modified by subsequent amendments and change orders.
We look forward to continuing to work with you to see the Study th rough to a successful conclusion.
Sincerely,
/s/ Xxxxx Xxxx
Xxxxx Xxxx
Managing Director
Accelovance Europe S.r.I.
| ACCELOVANCE EUROPE S.r.l. Socio Unico – Società soggetta a controllo e coordinamento da parte di ACCELOVANCE, Inc. | ||
Sede Operativa Via Xxxxxxx Xxxxx, 20099 Sesto San Giovanni (MI) – Italia Tel: x00 00 0000000 Fax: x00 00 00000000 |
Sede Legale Xxx Xxxxxx Xxxxxx, 00 00000 Xxxxxx
|
Cap. Soc. €1.000.000,00 i.v. P. IVA 12396690153 C.F. e N. iscrizione Reg. Imp. Milano 03777940374 xxx.xxxxxxxxxxx.xxx |
Acknowledged and agreeed on behalf of the Sponsor:
ADVANCED ACCELERATOR APPLICATIONS
| By: | /s/ Xxxxxxx Xxxxx | |
| Name: | Xxxxxxx Xxxxx | |
| Title: | Chief Executive Officer | |
| Date: | 11/14/2016 |
